De Novo Design of Proteins - Peptide and Protein Design for Biopharmaceutical Applications - page 246

induced fusion rather than assembly of the glycoprotein complex, PNAS , 91,
12676-12680 (1994).
[167] S. Liu, S. Wu and S. Jiang, HIV entry inhibitors targeting gp41: From polypeptides
to small-molecyle compounds, Curr. Pharm. Design , 13, 143-162 (2007).
[168] B. L. Bray, Large-scale manufacture of peptide therapeutics by chemical synthesis,
Nature Rev. Drug Discovery , 2, 587-593 (2003).
[169] S. E. Schneider, B. L. Bray, C. J. Mader, P. E. Friedrich, M. W. Anderson,
T. S. Taylor, N. Boshernitzan, T. E. Niemi, B. C. Fulcher, S. R. Whight,
J. M. White, R. J. Greene, L. E. Stoltenberg and M. Lichty, Development of HIV
fusion inhibitors, J. Pept. Sci ., 11, 744-753 (2005).
[170] S. W. Liu, S. G. Wu and S. B. Jiang, HIV entry inhibitors targeting gp41: From
polypeptides to small-molecule compounds, Curr. Pharm. Design , 13, 143-162
(2007).
[171] D. M. Eckert, V. N. Malashkevich, L. H. Hong, P. A. Carr and P. S. Kim, Inhibiting
HIV-1 entry: Discovery of D-peptide inhibitors that target the gp41 coiled-coil
pocket, Cell , 99, 103-115 (1999).
[172] D. M. Eckert and P. S. Kim, Design of potent inhibitors of HIV-1 entry from the
gp41 N-peptide region PNAS , 98, 11187-11192 (2001).
[173] M. J. Root, M. S. Kay and P. S. Kim, Protein design of an HIV-1 entry inhibitor,
Science , 291, 884-888 (2001).
[174] J. K. Judice, J. Y. K. Tom, W. Huang, T. Wrin, J. Vennari, C. J. Petropoulis and R. S.
McDowell, Inhibition of HIV type 1 infectivity by constrained a-helical peptides:
Inportance for the viral fusion mechanism, PNAS , 94, 13426-13430 (1997).
[175] S. K. Sia and P. S. Kim, Protein grafting of an HIV-1-inhibiting epitope, PNAS , 100,
9756-9761 (2003).
[176] A. Tossi, L. Sandri and A. Giangaspero, Amphipathic, a-helical antimicrobial
peptides, Biopolymers , 55, 4-30 (2000).
[177] P. I. Arvidsson, J. Frackenpohl, N. S. Ryder, B. Liechty, F. Petersen, H. Zimmerman,
G. P. Camenisch, R. Woessner and D. Seebach, On the antimicrobial and hemolytic
activities of amphiphilic b-peptides, ChemBioChem , 2, 771-773 (2001).
[178] Y. Hamuro, J. P. Schneider and W. F. DeGrado, De novo design of antibacterial
b-peptides, J. Am. Chem. Soc ., 121, 12200-122001 (1999).
[179] D. Liu and W. F. DeGrado, De novo design, synthesis, and characterization of
antimicrobial b-peptides, J. Am. Chem. Soc ., 123, 7553-7559 (2001).
[180] E. A. Porter, X. Wang, H.-S. Lee, B. Weisblum and S. H. Gellman, Antibiotics -
Non-haemolytic b-amino acid oliogomers, Nature , 404, 565-565 (2000).
[181] O. M. Stephens, S. Kim, B. D. Welch, M. E. Hodsdon, M. S. Kay and A. Schepartz,
J. Am. Chem. Soc ., 127, 13126-13127 (2005).
[182] A. J. Karlsson, W. C. Pomerantz, B. Weisblum, S. H. Gellman and S. P. Palecek,
Antifungal activity from 14-helical b-peptides, J. Am. Chem. Soc ., 128,

12630-12631 (2006).